Travere Therapeutics (TVTX) EBT Margin (2014 - 2026)
Travere Therapeutics (TVTX) posted EBT Margin of 28.87% for Q1 2026, down 582.06% on a QoQ basis from 5.99% in Q4 2025, and up 2152.0% year-over-year from 1.28% in Q1 2025.
Travere Therapeutics (TVTX) EBT Margin (2014 - 2026) Analysis & Trends
Travere Therapeutics' EBT Margin history runs 13 years deep, the most recent figure standing at 28.87% for Q1 2026.
- Quarterly EBT Margin rose 2152.0% year-over-year to 28.87% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 63.93% (up 14653.0% YoY) and the FY2025 annual result came in at 529.82%, down 39236.0% from the prior year.
- EBT Margin was 28.87% for Q1 2026 at Travere Therapeutics, down from 5.99% in the prior quarter.
- Across five years, EBT Margin topped out at 64.28% in Q3 2025 and bottomed at 348.94% in Q1 2022.
- A 5-year average of 172.31% and a median of 196.47% in 2023 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2022 — EBT Margin plunged 34777 bps — and 2025, when it soared 27775 bps.
- Travere Therapeutics' EBT Margin stood at 291.67% in 2022, then jumped by 33 bps to 196.47% in 2023, then surged by 59 bps to 80.68% in 2024, then jumped by 107 bps to 5.99% in 2025, then sank by 582 bps to 28.87% in 2026.
- Business Quant data shows TVTX's EBT Margin at 28.87% in Q1 2026, 5.99% in Q4 2025, and 64.28% in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Travere Therapeutics | 5.21 Bn | 5.21 Bn | 125.25 Mn | -28.87% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -28.87% |
| Dec 31, 2025 | 5.99% |
| Sep 30, 2025 | 64.29% |
| Jun 30, 2025 | -11.13% |
| Mar 31, 2025 | -50.39% |
| Dec 31, 2024 | -80.68% |
| Sep 30, 2024 | -87.18% |
| Jun 30, 2024 | -128.55% |
| Mar 31, 2024 | -328.15% |
| Dec 31, 2023 | -196.47% |
| Sep 30, 2023 | -240.54% |
| Jun 30, 2023 | -316.40% |
| Mar 31, 2023 | -312.37% |
| Dec 31, 2022 | -291.67% |
| Sep 30, 2022 | -298.91% |
| Jun 30, 2022 | -279.28% |
| Mar 31, 2022 | -348.94% |
| Dec 31, 2021 | 56.10% |
| Sep 30, 2021 | -52.18% |
| Jun 30, 2021 | -71.34% |